Buy the full study
Summary of our market study
The French contraceptive market is estimated at nearly €530 million in 2022.
The global market is estimated at around $22-23 billion, and is expected to reach $30 billion by 2027. This expansion is attributed to population growth, increased government initiatives to raise awareness of unwanted pregnancies and sexually transmitted infections (STIs), and changing lifestyles that delay childbearing.
France stands out in Europe for its relatively easy access to contraception, with a score of 90.1% for contraceptive accessibility in 2020.
The main players on the global market are Allergan Plc, Bayer AG and Merck.
The French contraceptive market
A variety of contraceptive methods are used, with hormonal pills, intrauterine devices (IUDs) and condoms being the most widespread.
In France, around a third of women opt for the contraceptive pill, a quarter for the IUD and around 16% for the condom.preferences change with age: women aged 15 to 34 prefer the pill, while those aged 35 to 49 prefer the IUD. Implants and combined pill/condom use each account for 5% of methods chosen.
The market has experienced what has been termed a "pill crisis", with extensive public and regulatory scrutiny of 3rd and 4th generation contraceptive pills due to the health risks associated with them. This controversy led to a drop in pill use from around 41% to 32%, with no significant increase in the number of women giving up contraception altogether. On the other hand, there has been a marked increase in the use of IUDs and condoms.
Key players in the contraception market: An overview of industry leaders
- Bayer AG: In the contraception market, Bayer has positioned itself as a specialist in 3rd and 4th generation contraceptive pills, with popular products such as Melodia, Melane and Jasmine. The company is also known for its intrauterine devices (IUDs), and has made an impact in the emergency contraception segment with its EllaOne product.
- Reckitt Benckiser Group (Durex): Reckitt Benckiser's Durex brand is a household name in sexual health, as it dominates the condom segment.
- LifeStyles Healthcare (Manix, Skyn): Known for its Manix and Skyn brands, LifeStyles Healthcare has carved out a significant share of the sexual wellness and condom market.
- MSD France (Merck): With a broad portfolio including various healthcare products, MSD France stands out in the contraceptive market for its pill and emergency contraception options.
- Effik: An Italian-based company that has made its mark on the French contraceptive market, mainly with oral contraceptives.
- 7 Med Industrie and CCD: These French companies have established a solid foothold, mainly in the intra-uterine device (IUD) segment.
- HRA Pharma: Another leading company in the emergency contraception sector, HRA Pharma is behind the famous Norlevo morning-after pill.
- Theramex: specialized in women's health care.
to understand this market
Detailed content of our market study
Inforamtion
- Number of pages : ~ 40 pages
- Format : Digital and PDF versions
- Last update :
Summary and extracts
1 Market overview
1.1 Definition and scope of the study
Contraception refers to all the methods used by men or women in order to make sexual intercourse infertile .
While the contraceptive pill remains the primary contraceptive method in France, there are many other means of contraception, of local or general action and of varying effectiveness and constraints :
- Locally acting methods (avoids pregnancy at the time of intercourse): male or female condom, spermicide, diaphragm, cervical cap
- Hormonal methods hormonally active substances of the estrogen or progestin type (pill, implant, injection, vaginal ring, patch, hormonal intrauterine device)
- Surgical methods definitive methods by laparoscopic or hysteroscopic route in women and by scrotal route in men.
- Natural Methods Methods that do not use external elements to regulate fertility (observation of the woman's menstrual cycle, Ogino method, calendar method, withdrawal method, etc.).
- Male Methods Thermal male contraception method by artificial cryptorchidism, the male pill
- After a report emergency contraception (morning-after pill, two-day pill and copper intrauterine device).
The global contraceptive market was worth 22.49 billion in 2019 The number of employees is expected to increase by 23.3% in 5 years, compared to 2014. This turnover is expected to grow at a CAGR (compound annual growth rate) of 5.5% between 2019 and 2027. This upward trend in sales is mainly due to demographic growth, rising standards of development and living standards, the generalisation of studies and the increasing place of women in the labour market, which is accompanied by a mutiplication of maternity deferrals
The french market of contraception is also progressing. This growth is mainly driven by the growing awareness of the French population to contraceptive methods and sexually transmitted infections (STIs), the player investments of the sector to develop innovative products and government initiatives supporting improved access to contraception and information on contraceptive solutions and Family Planning.
In France, the pill is still the first method used despite the "pill crisis" at the end of 2012. The intrauterine system (IUD or IUD) and the condom are used by respectively 25% and 16% french women.
List of charts presented in this market study
- Répartition des méthodes de contraception utilisées
- Évolution des méthodes de contraception utilisées
- Raisons d'arrêt de la pilule
- Marché français des dispositifs contraceptifs
- Prévisions de croissance sur le marché mondial de la contraception
All our studies are available online in PDF format
Take a look at an example of our research on another market!
Companies quoted in this study
This study contains a complete overview of the companies in the market, with the latest figures and news for each company. :
Choosing this study means :
Access to more than 35 hours of work
Our studies are the result of over 35 hours of research and analysis. Using our studies allows you to devote more time and added value to your projects.
Benefit from 6 years' experience and over 1,500 industry reports already produced
Our expertise enables us to produce comprehensive studies in all sectors, including niche and emerging markets.
Our know-how and methodology enable us to produce reports that offer unique value for money.
Access to several thousand articles and paid-for data
Businesscoot has access to all the paid economic press as well as exclusive databases to carry out its market research (over 30,000 articles and private sources).
To enhance our research, our analysts also use web indicators (semrush, trends, etc.) to identify market trends and company strategies. (Consult our paying sources)
Guaranteed support after your purchase
A team dedicated to after-sales service, to guarantee you a high level of satisfaction. +44 238 097 0676
A digital format designed for our users
Not only do you have access to a PDF, but also to a digital version designed for our customers. This version gives you access to sources, data in Excel format and graphics. The content of the study can therefore be easily retrieved and adapted for your specific needs.
Our offers :
the contraceptive market | France
- What are the figures on the size and growth of the market?
- What is driving the growth of the market and its evolution?
- What is the positioning of companies in the value chain?
- Data from several dozen databases
Pack 5 études (-15%) France
- 5 études au prix de 75,6€HT par étude à choisir parmi nos 800 titres sur le catalogue France pendant 12 mois
- Conservez -15% sur les études supplémentaires achetées
- Choisissez le remboursement des crédits non consommés au terme des 12 mois (durée du pack)
Consultez les conditions du pack et de remboursement des crédits non consommés.
Our customer references
They have consulted our studies
Discover the opinions (+500)
Malcolm Vincent
Astoria Finance
Gregoire de Castelnau
Stags Participations
Timothé Huignard
PWC
Paul-Alexis Kebabtchieff
BCG
Aymeric Granet
Publicis Consultant
interviews & case studies
All interviews and case studies (45)
